Inj fensolvi 0.25 mg
Products billed under this code include Fensolvi.
Payment limit per 0.25 MG, by effective quarter, 3Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Fensolvi.
Payment limit per 0.25 MG, by effective quarter, 3Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Fensolvi | Tolmar Inc. | 62935-0153-50 | 180 | $25,505.28 |
| Fensolvi | Tolmar Inc. | 62935-0163-60 | 180 | $25,505.28 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $141.696 | −$3.615 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted September 17, 2026 |
| 3Q26 | $145.311 | +$4.602 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted September 15, 2026 |
| 2Q26 | $140.709 | +$0.832 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted September 15, 2026 |
| 1Q26 | $139.877 | −$1.113 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted September 15, 2026 |
| 4Q25 | $140.99 | +$0.564 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted September 8, 2026 |
| 3Q25 | $140.426 | +$6.17 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted March 10, 2026 |
| 2Q25 | $134.256 | −$2.225 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted March 10, 2026 |
| 1Q25 | $136.481 | −$4.142 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted December 19, 2025 |
| 4Q24 | $140.623 | +$0.623 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted June 11, 2025 |
| 3Q24 | $140.00 | +$8.295 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted June 11, 2025 |
| 2Q24 | $131.705 | −$0.119 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted March 11, 2025 |
| 1Q24 | $131.824 | −$1.815 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted December 19, 2024 |
| 4Q23 | $133.639 | −$5.168 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted October 10, 2024 |
| 3Q23 | $138.807 | +$6.805 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted June 5, 2024 |
| 2Q23 | $132.002 | −$0.761 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted February 23, 2024 |
| 1Q23 | $132.763 | −$1.352 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted December 6, 2023 |
| 4Q22 | $134.115 | +$0.651 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted June 22, 2023 |
| 3Q22 | $133.464 | +$7.032 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted June 9, 2023 |
| 2Q22 | $126.432 | −$0.614 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted December 14, 2022 |
| 1Q22 | $127.046 | +$0.769 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted June 8, 2022 |
| 4Q21 | $126.277 | −$1.471 | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted June 2, 2022 |
| 3Q21 | $127.748 | – | 0.25 MG | Inj fensolvi 0.25 mg | v1, posted June 2, 2022 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.